CYP3A4 and COVID-19: Most statins are metabolized by CYP3A4 in the liver, however, in cases of simultaneous administrations of CYP3A4 inhibitors for COVID-19, such as ritonavir, it is recommended to start with lower doses of statins, while monitoring creatine kinase and transaminase levels.